Professional Documents
Culture Documents
Diagnosis Dini Preeklampsia Dan Eklampsia Dan Pencegahan Preeklampsia Dan Eklampsia
Diagnosis Dini Preeklampsia Dan Eklampsia Dan Pencegahan Preeklampsia Dan Eklampsia
• 5- MTHF
Introduction
• THE RIGHT SELECTION OF DIAGNOSIS AND PREVENTION METHOD CAN HELP
DECREASE THE MORTALITY AND MORBIDITY RATE ON BOTH THE MOTHER AND
THE FETUS.
• THE PLASEBO GROUP HAVE RELATIVE RISK 1.29 TIMES HIGHER THAN
THE ASPIRIN GROUP
DISCUSSION
• AT 11-13 WEEKS’ GESTATION, BIOPHYSICS MARKER USED IS UtA-PI AND
MATERNAL CHARACTERISTICS.
• THE DETECTION RATE OF COMBINATION FROM MATERNAL HISTORY
AND BIOPHYSICS MARKER IS 80%, 70%, AND 52% FOR PREECLAMPSIA
<34 WEEKS, <37 WEEKS, AND ALL PREGNANCY
• BIOMARKER USED ARE PAPP-A AND PIGF. COMBINATION FOR ALL
EXAMINATION ARE 88%, 75%, AND 54% FOR PREECLAMPSIA <34
WEEKS, <37 WEEKS, AND ALL PREGNANCY
• IN FIRST TRIMESTER, BIOMARKER USED IS PAPP-A AND PIGF
• sFLT-1 CAN BE USED AS A MARKER AFTER 15 WEEKS’ GESTATION
• DR OF MATERNAL CHARACTERISTICS, BIOPHYSICS MARKER, AND BIOCHEMISTRY
MARKER IN 37 WEEKS’ GESTATION ARE 47%, 81%, AND 71%
• BIOMARKER USED IN 19-24 WEEKS’ GESTATION IS sFLT-1 AND PAPP-A
• COMBINATION OF ALL EXAMINATION ARE 85% AND 44% FOR PREECLAMPSIA <37
WEEKS AND >37 WEEKS
• BIOPHYSICS EXAMINATION USING UtA-PI IN 11-13 WEEKS, 19-24 WEEKS, AND 30-
34 WEEKS HAS DR 39.9%, 43.1%, AND 41,5% FOR < 37 WEEKS PREGNANCY